Abstract
Statins are used widely for the treatment of cardiovascular (CV) disease because they improve the lipid profile and reduce the rate of coronary and cerebrovascular diseases. During the past 15 years, the overall risk profile of patients treated with statins has changed considerably, becoming more complex due to a progressive increase in the proportion of subjects with several concomitant diseases. Indeed, the presence of dyslipidemia is frequently associated with arterial hypertension, diabetes and the metabolic syndrome, as well as with CV and renal disease. In this patient population, the ideal statin should bear some properties that allow for both a substantial improvement in the lipid profile and a reduction in global CV risk. In particular, the ideal statin should provide both a reduction in total and LDL-C and an increase in HDL-C, effects that have been described for statins such as pitavastatin. The clinical efficacy of the ideal statin should be confirmed in a large population of patients and acr...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
